ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,482.87
0.09%
Dow Jones
39,164.06
0.09%
US Dollar vs MXN
18.4758
0.22%
Brent Oil
85.635
0.26%
Bitcoin
61,578.02
-0.05%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. IN8bio Inc (INAB)

  7. IN8bio Inc (INAB) Noticias

INAB

IN8bio (INAB)

IN8bio Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:INAB
FechaHoraFuenteTítuloSímboloCompañía
24/06/202407:00GlobeNewswire Inc.IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceNASDAQ:INABIN8bio Inc
14/06/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
13/06/202415:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INABIN8bio Inc
13/06/202415:01GlobeNewswire Inc.IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100NASDAQ:INABIN8bio Inc
03/06/202405:05GlobeNewswire Inc.IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:INABIN8bio Inc
24/05/202407:00GlobeNewswire Inc.IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024NASDAQ:INABIN8bio Inc
23/05/202416:00GlobeNewswire Inc.IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual MeetingNASDAQ:INABIN8bio Inc
14/05/202409:00GlobeNewswire Inc.IN8bio Announces Upcoming Presentation at 2024 European Hematology Association CongressNASDAQ:INABIN8bio Inc
13/05/202407:00GlobeNewswire Inc.IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024NASDAQ:INABIN8bio Inc
09/05/202415:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INABIN8bio Inc
09/05/202415:00GlobeNewswire Inc.IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:INABIN8bio Inc
07/05/202415:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:INABIN8bio Inc
30/04/202405:05GlobeNewswire Inc.IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed GlioblastomaNASDAQ:INABIN8bio Inc
24/04/202407:00GlobeNewswire Inc.IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:INABIN8bio Inc
16/04/202415:05GlobeNewswire Inc.IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceNASDAQ:INABIN8bio Inc
09/04/202415:30GlobeNewswire Inc.IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024NASDAQ:INABIN8bio Inc
14/03/202415:00GlobeNewswire Inc.IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsNASDAQ:INABIN8bio Inc
05/03/202415:30GlobeNewswire Inc.IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024NASDAQ:INABIN8bio Inc
26/02/202407:00Business WireIN8bio to Present at Upcoming Investor ConferencesNASDAQ:INABIN8bio Inc
14/02/202407:00GlobeNewswire Inc.IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyNASDAQ:INABIN8bio Inc
19/01/202415:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INABIN8bio Inc
18/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:INABIN8bio Inc
18/01/202415:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:INABIN8bio Inc
12/01/202416:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:INABIN8bio Inc
04/01/202407:00GlobeNewswire Inc.IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline GoalsNASDAQ:INABIN8bio Inc
28/12/202311:28Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:INABIN8bio Inc
15/12/202315:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INABIN8bio Inc
15/12/202305:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
11/12/202315:05GlobeNewswire Inc.IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in LeukemiaNASDAQ:INABIN8bio Inc
11/12/202308:00GlobeNewswire Inc.IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private PlacementNASDAQ:INABIN8bio Inc
 Showing the most relevant articles for your search:NASDAQ:INAB

Su Consulta Reciente

BIT
P20ZM3
NLBNPIT20ZM3 20250620 39...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados